scispace - formally typeset
R

Ralph B. D'Agostino

Researcher at Wake Forest University

Publications -  1336
Citations -  250792

Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.

Papers
More filters
Journal ArticleDOI

Intensity and Amount of Physical Activity in Relation to Insulin Sensitivity: The Insulin Resistance Atherosclerosis Study

Elizabeth J. Mayer-Davis, +6 more
- 04 Mar 1998 - 
TL;DR: Increased participation in nonvigorous as well as overall and vigorous physical activity was associated with significantly higher insulin sensitivity, and these findings lend further support to current public health recommendations for increased moderate-intensity physical activity on most days.
Journal ArticleDOI

Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics

Ralph B. D'Agostino, +4 more
- 18 Dec 2002 - 
TL;DR: The non‐inferiority trial is appropriate for evaluation of the efficacy of an experimental treatment versus an active control when it is hypothesized that the experimental treatment may not be superior to a proven effective treatment, but is clinically and statistically not inferior in effectiveness.
Journal ArticleDOI

Tests for departure from normality. Empirical results for the distributions of b2 and √b1

Ralph B. D'Agostino, +1 more
- 01 Dec 1973 - 
Journal ArticleDOI

Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus The Framingham Heart Study

Caroline S. Fox, +8 more
- 27 Mar 2007 - 
TL;DR: The proportion of CVD attributable to diabetes mellitus has increased over the past 50 years in Framingham, emphasizing the need for increased efforts to prevent DM and to aggressively treat and control CVD risk factors among those with DM.
Journal ArticleDOI

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Theodore Mazzone, +8 more
- 06 Dec 2006 - 
TL;DR: Over an 18-month treatment period in patients with type 2 DM, pioglitazone slowed progression of CIMT compared with glimepiride and was similar across prespecified subgroups based on age, sex, systolic blood pressure, duration of DM, body mass index, HbA(1c) value, and statin use.